Canada’s first gluten-free food service training guide improves patient health & saves lives.
January 23, 2024 12:32 ET
|
Celiac Canada
TORONTO, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Celiac patients in hospitals and long-term care residents who cannot advocate for themselves are often served food containing gluten, which can lead to...
First Wave BioPharma to Present at the DealFlow MicroCap Conference
January 23, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
January 17, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
January 05, 2024 16:01 ET
|
Barinthus Biotherapeutics
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
January 04, 2024 06:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
December 27, 2023 06:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company
December 18, 2023 06:00 ET
|
First Wave BioPharma, Inc.
Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal (GI) disease clinical pipeline A concurrent...
Fecal Calprotectin Test Market revenue to hit USD 350 Million by 2035, says Research Nester
August 23, 2023 07:30 ET
|
Research Nester
New York, Aug. 23, 2023 (GLOBE NEWSWIRE) -- The global fecal calprotectin test market size is predicted to grow at a CAGR of over ~12% from 2023 to 2035. The market is projected to garner a revenue...
8.4% CAGR for Capsule Endoscopy Market Size Worth $757.51 Million by 2028 – Deep Dive Analysis of 18+ Countries across 5 Key Regions, 50+ Companies Scrutinized | The Insight Partners
March 09, 2023 08:51 ET
|
The Insight Partners
New York, March 09, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Capsule Endoscopy Market Size, Share, Growth and Global Forecast to 2028 - COVID-19 Impact and Global Analysis By...
Canadian Celiac Association is Setting the Record Straight
May 03, 2021 10:53 ET
|
Canadian Celiac Association
TORONTO, May 03, 2021 (GLOBE NEWSWIRE) -- May is Celiac Awareness Month and the Canadian Celiac Association (CCA) is setting the record straight for Canadians suffering with celiac disease. An...